Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: neurodegenerative disease therapeutics - ProMIS Neurosciences

Next Previous
Drug Profile

Research programme: neurodegenerative disease therapeutics - ProMIS Neurosciences

Alternative Names: PMN 267 - ALS therapeutic; PMN 300; PMN 320; PMN 330; PMN 340; PMN 350; TDP 43 targeting therapeutics

Latest Information Update: 04 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amorfix Life Sciences
  • Developer ProMIS Neurosciences
  • Class Antidementias; Antiparkinsonians; Monoclonal antibodies; Neuroprotectants
  • Mechanism of Action Alpha-synuclein modulators; Amyloid beta-protein modulators; Superoxide dismutase inhibitors; Tau protein inhibitors; TDP-43 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Alzheimer's disease; Amyotrophic lateral sclerosis; Dementia; Down syndrome; Lewy body disease; Multiple system atrophy; Parkinson's disease

Most Recent Events

  • 24 Mar 2025 Pharmacodynamics data from a preclinical proof-of-concept trial released by ProMIS Neurosciences
  • 28 Aug 2024 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in Canada (Parenteral)
  • 28 Nov 2023 No recent reports of development identified for preclinical development in Multiple system atrophy in Canada (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top